- AU$15.80m
- AU$19.47m
Australia's Imugene up on advancing trial for cancer drug to next cohort
Brief: Imugene Says FDA Clears IND To Commence Oncarlytics Clinical Study
Australia's Imugene climbs on FDA clearance for clinical study
Brief: Imugene Posts HY Loss A$17.4 Million
Australia's Imugene rises on U.S. patent grant for its immunotherapy product
Australian healthcare stocks rally, CSL hits 14-month high
Australia's Imugene hits one week high after cancer treatment trial clears milestone
Brief: Celularity Completes Strategic Review Of 2023 Initiatives
Brief: Imugene Imugene Receives Vaxinia Ethics Approval In Australia
Australia's Imugene climbs on ethics approval for cancer treatment trial
Brief: Imugene Partners with ABL To Advance advance VAXINIA manufacturing
Australia's Imugene rises on licence to expand study of cancer treatment
Australia's Imugene slips most in two months on discounted placement
Brief: Imugene Announces A$80 Million Institutional Placement
Brief: Imugene Ltd Seeks Trading Halt
Australia's Imugene tops the ASX 200, at an over four-month high
Aussie healthcare stocks post biggest half-year drop since 2008 financial crisis
Australia's Imugene jumps on 'favourable' survival outcome in immunotherapy candidate trial
Australian healthcare stocks mark worst session since Dec on broader market woes